• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of molcellbPermissionsJournals.ASM.orgJournalMCB ArticleJournal InfoAuthorsReviewers
Mol Cell Biol. Aug 2006; 26(15): 5888–5894.
PMCID: PMC1592765

Forebrain-Specific Inactivation of Gq/G11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation


Metabotropic receptors coupled to Gq/G11 family G proteins critically contribute to nervous system functions by modulating synaptic transmission, often facilitating excitation. We investigated the role of Gq/G11 family G proteins in the regulation of neuronal excitability in mice that selectively lack the α-subunits of Gq and G11, Gαq and Gα11, respectively, in forebrain principal neurons. Surprisingly, mutant mice exhibited increased seizure susceptibility, and the activation of neuroprotective mechanisms was impaired. We found that endocannabinoid levels were reduced under both basal and excitotoxic conditions and that increased susceptibility to kainic acid could be normalized by the enhancement of endocannabinoid levels with an endocannabinoid reuptake inhibitor, while the competitive cannabinoid type 1 receptor antagonist SR141716A did not cause further aggravation. These findings indicate that Gq/G11 family G proteins negatively regulate neuronal excitability in vivo and suggest that impaired endocannabinoid formation in the absence of Gq/G11 contributes to this phenotype.

Several metabotropic receptors of the central nervous system signal through heterotrimeric G proteins of the Gq/G11 family, for example, the metabotropic glutamate receptor subtypes 1 and 5, the M1 muscarinic acetylcholine receptor, and the 5-hydroxytryptamine 2 (5-HT2) serotonin receptor. Stimulation of Gq/G11-coupled receptors causes the activation of phospholipase C-β (PLC-β) isoforms, leading to inositol phospholipid breakdown, protein kinase C activation, and intracellular calcium mobilization (18). Gq/G11-coupled receptors have been shown to contribute to the modulation of synaptic transmission in the hippocampus and cerebellum (1, 23, 25, 33, 37, 46, 48) and are known to facilitate neuronal activation by opening voltage-dependent cation channels and closing potassium channels (10, 12). In line with this, agonists at the Gq/G11-coupled metabotropic glutamate receptors or the muscarinic acetylcholine receptors promote seizures in vitro and in vivo (6, 11, 57), while antagonists at these receptors have been suggested to have anticonvulsive effects (7, 8).

In vitro data, however, indicate that Gq/G11-coupled receptors can also indirectly exert inhibitory effects through the inhibition of presynaptic calcium channels (22, 45) or the activation of the endocannabinoid system. Endocannabinoids such as anandamide and 2-arachidonoyl glycerol (2-AG) are lipophilic neuromodulators that are synthesized and released “on demand” in postsynaptic neurons in response to depolarization-induced calcium influx (14, 34, 50, 69) or activation of Gq/G11-coupled metabotropic receptors (20, 21, 32, 38, 41, 51, 52, 65). Both transmembrane Ca2+ influx and Gq/G11-mediated intracellular Ca2+ mobilization enhance anandamide biosynthesis via an N-acyltransferase and a specific phospholipase D-like enzyme (13, 15, 16, 56, 61, 62). In parallel, Gq/G11-mediated PLC-β activation results in the production of diacylglycerol (DAG), which serves as a precursor for 2-AG via Ca2+-sensitive sn-1-DAG lipases (3). PLC-β, DAG, and sn-1-DAG lipase were suggested to be of special importance for the production of that pool of 2-AG that functions as an endocannabinoid precursor, especially in response to neuronal depolarization and in retrograde signaling (9, 16, 44, 56, 62, 63). Endocannabinoids act mostly via presynaptic cannabinoid type 1 receptors to inhibit neurotransmitter release at inhibitory as well as excitatory synapses (2, 19, 68), and they were shown to protect the brain from excitotoxicity and other forms of neuronal damage (16, 43, 56, 62, 63). However, the relative weight and function of Gq/G11-mediated signaling in the regulation of endocannabinoid levels in vivo are unclear. It is also not clear whether the net effect of Gq/G11 signaling in vivo is excitatory or inhibitory.

The two main members of the Gq/G11 family are Gq and G11, which are almost ubiquitously expressed in the central nervous system and have highly redundant functions. Since genetic inactivation of both Gαq and Gα11 causes embryonic lethality (49), we employed the Cre/loxP system to generate mice which allow tissue-specific inactivation of Gαq in constitutively Gα11-deficient mice (67). These mice were crossed with the Camkcre4 mouse line (39), which causes recombination selectively in principal neurons of the forebrain (40). Forebrain-specific Gαq/Gα11 double knockout (fb-Gαq/Gα11-DKO) mice were viable and fertile and showed normal basic sensory and motor abilities, but females were unable to raise normal maternal behavior toward their young (66). We used fb-Gαq/Gα11-DKO mice to investigate the role of Gq/G11 in the regulation of neuronal excitability, with a special focus on the role of Gq/G11 in endocannabinoid synthesis.



Genotyping for the gnaqflox allele, the gna11 wild-type and knockout alleles, and the Cre transgene was described previously (67). The primers used for detecting the Camkcre4 transgene were 5′-TCTCCATTTGCACTCAGGAGC-3′ and 5′-AAAACGCCTGGCGATCCCT-G-3′. Mice were housed under specific-pathogen-free conditions, and all animal experiments were performed in accordance with institutional animal care and use committee regulations. The genetic background of the mice was predominantly C57BL6/N (fourth-generation backcross), and nonlittermate C57BL6/N mice or littermates with the Camkcre4/ gnaqfl/fl gna11wt/wt genotype were used as controls. No significant differences were observed between the two control groups.

Animal experiments.

Kainic acid (KA; Sigma, Deisenhofen, Germany) and pentylenetetrazole (PTZ; Sigma) were dissolved in saline and administered intraperitoneally (i.p.) at the indicated dosages. N-Piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolone-carboxamide (SR141716A; Cayman Chemical, Ann Arbor, MI) and OMDM-2 [(R)-N-oleoyl-(1′-hydroxybenzyl)-2′-ethanolamine] (synthesized as previously described [(54]) were dissolved in Tween 80-ethanol-0.9% saline (1:1:18) and injected i.p. 30 min before KA treatment at the concentrations indicated in the figure legends (for six to eight mice per group). Mice were monitored for 60 min, and responses were scored every 5 minutes by an observer blinded to the genotype, as described previously (24). Briefly, responses were scored as follows: 0, normal behavior; 1, rigid or slowed walking; 2, isolated jerks; 3, repetitive jerks; 4, forelimb clonus, isolated clonic jerks; 5, repetitive clonic jerks, mouse on its side with fore- and hindlimb clonus; 6, death. Video and electroencephalography (EEG) monitoring of mice were performed as described previously (35).


Mice were deeply anesthetized with pentobarbital, 100 mg/kg of body weight i.p., and perfused with 4% paraformaldehyde via the left cardiac ventricle. Their brains were postfixed overnight and then stored in 0.5% paraformaldehyde at 4°C. Fifty-micrometer vibratome sections were cut and incubated at 4°C with antibodies directed against the following proteins: c-fos protein (sc-52; Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:20,000, incubated for 72 h); zif-268 (Santa Cruz Biotechnology; diluted 1:200, incubated for 72 h); Gαq/Gα11 (sc-392; Santa Cruz Biotechnology; diluted 1:1,000, incubated for 16 h); GFAP (DAKO, Glostrup, Denmark; diluted 1:500, incubated for 16 h); NeuN (Chemicon, Temecula, CA; diluted 1:2,000, incubated for 16 h); GAD67 (Chemicon; diluted 1:2,000, incubated for 16 h); calbindin (Chemicon; diluted 1:2,000, incubated for 16 h); calretinin (Chemicon; diluted 1:5,000, incubated for 16 h); and MAP2 (Chemicon; diluted 1:1,000, incubated for 16 h). For staining we used the Vectastain Elite ABC kits (Vector Labs, Burlingame, CA) and diaminobenzidine (Vector Labs). Nissl staining was performed according to standard protocols. Timm staining was performed as described previously (5). Sections were photographed using a Leica DMLB microscope and a Leica DC300F camera (Leica, Bensheim, Germany). The numbers of c-fos- or zif-268-positive cells were counted manually or with a CellExplorer 2003 program (BioSciTec, Germany) by investigators blinded to genotype and treatment. For each group of mice, two sections from each of four animals were analyzed.

Endocannabinoid levels.

Mice (six to eight per group) were sacrificed 20 min after injection of 20 mg/kg kainate, and hippocampi were rapidly dissected, snap-frozen, and stored at −80°C. Endocannabinoids were extracted, and their levels were measured by isotope dilution liquid chromatography-mass spectrometry as described previously (40).


Hippocampal sections from 3- to 5-week-old forebrain-specific Gaq/Ga11 double knockout mice and wild-type mice were prepared as described previously (53). Recordings were made from CA1 pyramidal neurons in slices with patch pipettes pulled from 1.5-mm-outer-diameter, thick-walled glass tubing (1511-M; Friedrich & Dimmock). Whole-cell tight seals (>2 GΩ) were made on the soma under visual control with a 40× water immersion lens. Cells were identified as pyramidal neurons by using both electrical and anatomical criteria. Capacitance was fully compensated for by a patch clamp amplifier (EPC-9; HEKA). The holding potential was −60 or −70 mV. The range of series resistances we accepted for recordings was 10 to 15 MΩ. Bipolar stimulation electrodes constructed from thin tungsten wires (50-μm outer diameter) were placed on the stratum radiatum in the CA2 to CA3 pyramidal regions. For inhibitory postsynaptic current (IPSC) recording, the pipette solution contained 130 mM CsCl, 5 mM KCl, 5 mM NaCl, 10 mM HEPES, 0.6 mM EGTA, 4 mM Mg-ATP, and 0.3 mM GTP, with the pH adjusted to 7.3 with NaOH. A non-N-methyl-d-aspartate (non-NMDA) receptor antagonist (6-cyano-7-nitroquinoxalline-2,3-dione, 20 μM) and an NMDA antagonist (dl-2-amino-5-phosphonovaleric acid, 50 μM) were always added to the perfusing solution. The CB1 receptor agonist WIN55,212-2 {R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate} was applied at 5 mM. Single traces are averaged from five consecutive IPSCs acquired before and at the end of the WIN55,212-2 application. Chemicals were obtained from Sigma-Aldrich Co.


All data except electrophysiological data are presented as means ± standard error of the means; electrophysiological data are presented as means ± standard deviations. Data were analyzed by analysis of variance followed by Bonferroni's post-hoc test. Statistical analysis was performed by repeated-measure two-way analysis of variance for the factors “treatment” and “genotype” and the interaction “treatment/genotype.”


Starting at the age of about 3 months, fb-Gαq/Gα11-DKO mice showed spontaneous epileptic seizures, and both the frequency of seizures in each animal and the number of affected animals increased with age (Fig. (Fig.1A).1A). The most frequent forms of seizure were mild myoclonic seizures, and combined EEG and video monitoring of mutant mice showed a series of rhythmic spikes (0.2 ± 0.03 Hz; 45 s, 7-min duration; 0 to 5 times a day) (Fig. (Fig.1B,1B, left panel) concomitant with myocloni of the body. Such episodes were not observed in wild-type animals (Fig. (Fig.1B,1B, right panel). Some animals also experienced clonic-tonic seizures, leading to an age-dependent reduction of survival (Fig. (Fig.1C1C).

FIG. 1.
Spontaneous epileptic seizures in fb-Gαq/Gα11-DKO mice. (A) Percentages of fb-Gαq/Gα11-DKO mice (KO; n = 30) (triangles) and control mice (WT; n = 30) (squares) with epileptic seizures. (B) Cortical EEGs ...

Histological and immunohistochemical analyses of mice younger than 3 months did not show abnormalities (data not shown). However, older mice, especially those with symptomatic epilepsy, showed neuronal degeneration and reactive gliosis in the hippocampal CA1 region, indicative of temporal lobe epilepsy (Fig. (Fig.2).2). In contrast to other models of temporal lobe epilepsy, we did not observe mossy fibers sprouting in sections visualized by Timm staining (data not shown).

FIG. 2.
Histological changes in hippocampi of fb-Gαq/Gα11-DKO mice. Hippocampal sections from 8-month-old control mice (upper row) and fb-Gαq/Gα11-DKO mice (lower row) stained with antibodies against Gαq/Gα11, NeuN, ...

To investigate whether abnormalities in neuronal excitability are present before the onset of spontaneous seizures, we studied the effects of chemical convulsants in 6- to 10-week-old fb-Gαq/Gα11-DKO mice in vivo. We found that the application of the glutamate receptor agonist KA or the gamma aminobutyric acid type A (GABAA) receptor antagonist PTZ induced stronger seizures in fb-Gαq/Gα11-DKO mice than in wild-type mice (Fig. 3A and C) and that mutant mice exhibited seizures at dosages that were already subconvulsive in wild-type mice (Fig. (Fig.3A).3A). Latency to seizure onset was decreased in fb-Gαq/Gα11-DKO mice (Fig. 3B and D), while seizure-associated lethality was strongly increased (data not shown). Mice with a single deficiency in Gαq or Gα11 showed mildly increased seizure susceptibility when challenged with kainic acid (see Fig. S1 in the supplemental material).

FIG. 3.
Increased sensitivities toward chemical convulsants of 6- to 10-week-old fb-Gαq/Gα11-DKO mice compared with those of control mice. Seizure scores (A and C) and latency periods (B and D) to first clonic-tonic (ct) convulsions after intraperitoneal ...

KA-induced seizures have been shown to be accompanied by enhanced expression of immediate early genes like c-fos, fosB, or zif-268 in the hippocampi of wild-type mice (30), and especially c-fos expression appears to be critically involved in the protection against KA-induced excitotoxicity (40, 70). To test whether the impaired activation of potentially neuroprotective pathways may contribute to increased seizure susceptibility in fb-Gαq/Gα11-DKO mice, we investigated the expression of c-fos and zif-268 proteins in untreated and KA-treated wild-type and mutant mice (Fig. (Fig.4).4). Compared to the upregulation in wild-type mice, the KA-induced upregulation of both proteins was almost abrogated in hippocampi from fb-Gαq/Gα11-DKO mice (Fig. (Fig.4),4), suggesting that neuroprotective mechanisms are impaired in these mice.

FIG. 4.
Kainate-induced upregulation of immediate early genes is impaired in fb-Gαq/Gα11-DKO mice. (A and B) Staining with antibodies against c-fos (A) and zif-268 (B) proteins in the hippocampi of control and fb-Gαq/Gα11-DKO mice ...

Since increased excitability and impaired immediate early gene activation are also observed in mice lacking endocannabinoid CB1 receptors in principal forebrain neurons and since the Gq/G11 G proteins have been involved in endocannabinoid synthesis, we determined the levels of anandamide and 2-AG in the hippocampi of wild-type and fb-Gαq/Gα11-deficient mice (Fig. (Fig.5).5). Under basal conditions, anandamide levels were significantly lower in mutant mice than in controls (Fig. (Fig.5A),5A), while 2-AG levels did not differ significantly (Fig. (Fig.5B).5B). The chemical convulsant KA enhanced both anandamide and 2-AG levels in control mice (Fig. 5A and B). Interestingly, KA treatment still increased anandamide levels in fb-Gαq/Gα11-DKO mice but failed to induce 2-AG synthesis (Fig. 5A and B). In mice with a single deficiency in Gαq or Gα11, KA-induced synthesis of 2-AG was also impaired, but the reduction was less prominent than in fb-Gαq/Gα11-deficient mice (see Fig. S1 in the supplemental material). These data indicate that basal hippocampal levels of anandamide, but not of 2-AG, are under tonic control of the Gq/G11-mediated signaling pathway. In contrast, Gq/G11-mediated signaling is necessary for KA-induced formation of 2-AG but not of anandamide.

FIG. 5.
Endocannabinoid levels in hippocampi of fb-Gαq/Gα11-DKO mice. (A and B) Anandamide (AEA) (A) and 2-AG (B) levels were determined by isotope dilution liquid chromatography-mass spectrometry in hippocampi from control and fb-Gαq ...

To further test whether the reduced formation of endocannabinoids in the absence of Gaq/Gα11 is involved in abnormal neuronal excitability and impaired neuroprotection, we pretreated mice with the CB1 receptor antagonist SR141716A. As expected, SR141716A strongly aggravated KA-induced seizures in wild-type mice (Fig. (Fig.6A).6A). However, in fb-Gαq/Gα11-DKO mice, a blockade of CB1 receptors did not further aggravate KA-induced seizures (Fig. (Fig.6A).6A). In this experiment, KA was administered at the reduced dosage of 10 mg/kg to detect the potential aggravation of seizure intensity in fb-Gαq/Gα11-DKO mice as well, which have per se higher seizure scores than wild-type mice (see Fig. Fig.3).3). Since SR141716A is a competitive antagonist at the CB1 endocannabinoid receptor, the lack of SR141716A aggravation of KA-induced seizures in fb-Gαq/Gα11-DKO mice supports our finding that endogenous levels of endocannabinoids are significantly decreased in fb-Gαq/Gα11-DKO mice, at least at those synapses involved in CB1-mediated neuroprotection. To enhance endocannabinoid levels selectively at sites of physiological production, we treated mice with the endocannabinoid reuptake inhibitor OMDM-2 (54). OMDM-2 caused a slight but nonsignificant amelioration of seizures induced by 30 mg/kg KA in wild-type mice but a strong amelioration in fb-Gαq/Gα11-DKO mice (Fig. (Fig.6B),6B), suggesting that endocannabinoid-mediated effects are basically functional in mutant mice. To further substantiate this notion, we investigated cannabinoid-mediated retrograde inhibition of synaptic transmission by electrophysiological means. In both the wild-type and the mutant hippocampal slices, the application of the CB1 receptor agonist WIN55,212-2 caused a significant reduction in the amplitude of IPSCs in CA1 hippocampal neurons (see Fig. S2 in the supplemental material). Taken together, both pharmacological and electrophysiological data indicate that endocannabinoid-mediated protective mechanisms are basically intact in fb-Gαq/Gα11-DKO mice but that endogenous cannabinoid production is impaired.

FIG. 6.
Pharmacological manipulation of the endocannabinoid system in wild-type and fb-Gαq/Gα11-DKO mice. (A and B) Effect of the competitive CB1 antagonist SR141716A (A) and the endocannabinoid reuptake inhibitor OMDM-2 (B) on kainic acid-induced ...


In this study we have shown that genetic inactivation of the Gq/G11-mediated signaling pathway in principal forebrain neurons results in increased neuronal excitability. This finding was unexpected since the modulatory effects of Gq/G11-mediated signaling are believed to facilitate rather than dampen neuronal activity. However, increased seizure susceptibility was also found in mice lacking PLC-β1 (31), the inositol 1,4,5-trisphosphate receptor (42), or the Gq/G11-coupled 5-HT2c receptor (60), suggesting that the Gq/G11-mediated signaling pathway indeed exerts important inhibitory effects.

Only a few Gq/G11-mediated effects that might promote neuronal inhibition have been described. Gq/G11-coupled receptors are present on hippocampal interneurons (26, 64), and impaired activation of these cells might shift the balance between excitation and inhibition. However, since Cre-mediated recombination in the Camkcre4 mouse line is restricted to principal neurons (40), this model obviously does not apply here. Some Gq/G11-coupled receptors, e.g., the M1 acetylcholine receptor, have been suggested to negatively regulate N-type calcium channels through a breakdown of membrane phosphatidylinositol 4,5-biphosphate (29) and thereby might contribute to inhibition. However, given the fact that a majority of inhibitory presynaptic G protein-coupled receptors, such as adenosine A1, α2 adrenergic μ and δ opioid, and GABAB receptors, signal through Gi/o family G proteins (17, 45), the contribution of Gq/G11-coupled receptors to calcium channel regulation seems to be rather small. Also, the endocannabinoid CB1 receptor is known to mediate its presynaptic inhibitory effects through Gi/o family G proteins (27, 28, 47, 55). It was recently reported that the synthetic CB1 agonist WIN55,212-2 induces a calcium response in CB1-transfected HEK293 cells in a Gq/G11-dependent manner; however, natural CB1 agonists such as Δ9-tetrahydrocannabinol, 2-AG, and anandamide analogues did not elicit such responses (36).

Though not directly coupled to CB1, the Gq/G11-mediated signaling pathway was suggested to contribute to endocannabinoid functions through its role in endocannabinoid synthesis. We found that hippocampal levels of anandamide, but not of 2-AG, are reduced in the absence of Gαq/Gα11, indicating that anandamide formation is under the tonic control of receptors coupled to these G proteins, while 2-AG formation is not. Muscarinic and purinergic receptors are among the G protein-coupled receptors that might contribute to basal anandamide levels as they are able to induce anandamide formation in the absence of extracellular Ca2+ as well (61). On the other hand, in the formation of basal 2-AG levels as previously described, PLC-β-independent biosynthetic routes (4, 59) seem to predominate.

In contrast to basal 2-AG production, Gq/G11-mediated signaling is indispensable for hippocampal 2-AG formation following KA application, and this might be due to the fact that DAG, a fundamental precursor of that pool of 2-AG that acts as an endocannabinoid (13, 15, 70), is mostly formed in depolarized neurons following the activation of PLC-β (58). In contrast to 2-AG formation in response to KA, Gq and G11 are not necessary for KA-induced anandamide formation. This observation supports the concept that anandamide can be produced in response to either metabotropic (61) or ionotropic (15) receptor stimulation alone, provided that the intracellular Ca2+ concentration is increased in order to induce the activation of Ca2+-sensitive biosynthesizing enzymes and the subsequent processing of non-PLC-β-derived biosynthetic precursors (54). With respect to the differential role of the two endocannabinoids in control of excitability, it is important to note that in wild-type mice, KA-induced 2-AG concentrations are at least 50-fold higher than the anandamide concentrations, and the loss of KA stimulation therefore results in much lower total endocannabinoid concentrations in fb-Gαq/Gα11-DKO mice than in wild-type mice (a net increase of 0.06 plus 3.35 or 3.41 nmol/g tissue in wild-type mice compared to a net decrease of 0.12 to 0.3 or −0.18 nmol/g tissue in fb-Gαq/Gα11-DKO mice) (Fig. (Fig.55).

The phenotype of CB1 receptor-deficient mice resembles that of fb-Gαq/Gα11-DKO mice in that both mouse strains have increased seizure susceptibilities in response to KA and inabilities to induce expression of immediate early genes encoding the c-fos and zif-268 transcription factors, which are believed to counteract excitotoxic damage (40, 70). This supports the hypothesis that impaired endocannabinoid-mediated retrograde signaling underlies increased neuronal excitability in fb-Gαq/Gα11-DKO mice. However, forebrain-specific CB1-deficient mice seem to be less prone to spontaneous epilepsy, although seizures have been observed in these animals, especially during the stress of handling (B. Lutz, personal communication). This phenotypic difference might be explained by the presence of non-CB1 (13, 16, 19, 56) receptors on hippocampal principal neurons, which contributes to endocannabinoid-mediated neuroprotection. In addition, defects in other Gq/G11-mediated processes which occur independently of endocannabinoids and which under normal conditions decrease neuronal activity, like the above-mentioned negative regulation of N-type Ca2+ channels, may contribute to the more-severe phenotype observed in fb-Gαq/Gα11-DKO mice.

Taken together, our data suggest that the Gq/G11-mediated signaling pathway is critically involved in endocannabinoid synthesis under both basal and excitotoxic conditions. The phenotypical similarities between forebrain-specific CB1-deficient mice and pharmacological in vivo data indicate that impaired endocannabinoid formation is associated with increased seizure susceptibility and impaired neuroprotection. However, defective endocannabinoid synthesis may not account exclusively for the increased neuronal excitation in the absence of Gq/G11, and other Gq/G11-mediated inhibitory mechanisms may contribute to the phenotype.

Supplementary Material

[Supplemental material]


We thank Barbara Wallenwein, Anke Rogatzki, Marianne Hillesheim, and Marta Valenti for expert technical assistance and Maria Pritsch, University of Heidelberg, for help with the statistical analysis.

This work was funded by the Volkswagenstiftung (to V.D.M.) and by the Collaborative Research Center 488 of the Deutsche Forschungsgemeinschaft (to S.O.).


Supplemental material for this article may be found at http://mcb.asm.org/.


1. Aiba, A., M. Kano, C. Chen, M. E. Stanton, G. D. Fox, K. Herrup, T. A. Zwingman, and S. Tonegawa. 1994. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 79:377-388. [PubMed]
2. Alger, B. E. 2002. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68:247-286. [PubMed]
3. Bisogno, T., F. Howell, G. Williams, A. Minassi, M. G. Cascio, A. Ligresti, I. Matias, A. Schiano-Moriello, P. Paul, E. J. Williams, U. Gangadharan, C. Hobbs, V. Di Marzo, and P. Doherty. 2003. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163:463-468. [PMC free article] [PubMed]
4. Bisogno, T., D. Melck, L. De Petrocellis, and V. Di Marzo. 1999. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72:2113-2119. [PubMed]
5. Bouilleret, V., V. Ridoux, A. Depaulis, C. Marescaux, A. Nehlig, and G. Le Gal La Salle. 1999. Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Neuroscience 89:717-729. [PubMed]
6. Camon, L., P. Vives, N. de Vera, and E. Martinez. 1998. Seizures and neuronal damage induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5-dihydroxyphenylglycine. J. Neurosci. Res. 51:339-348. [PubMed]
7. Chapman, A. G., K. Nanan, M. Williams, and B. S. Meldrum. 2000. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39:1567-1574. [PubMed]
8. Chapman, A. G., P. K. Yip, J. S. Yap, L. P. Quinn, E. Tang, J. R. Harris, and B. S. Meldrum. 1999. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur. J. Pharmacol. 368:17-24. [PubMed]
9. Chevaleyre, V., and P. E. Castillo. 2003. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38:461-472. [PubMed]
10. Chuang, S. C., R. Bianchi, D. Kim, H. S. Shin, and R. K. Wong. 2001. Group I metabotropic glutamate receptors elicit epileptiform discharges in the hippocampus through PLCbeta1 signaling. J. Neurosci. 21:6387-6394. [PubMed]
11. Conn, P. J., and J. P. Pin. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:205-237. [PubMed]
12. Delmas, P., M. Crest, and D. A. Brown. 2004. Functional organization of PLC signaling microdomains in neurons. Trends Neurosci. 27:41-47. [PubMed]
13. De Petrocellis, L., M. G. Cascio, and V. Di Marzo. 2004. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141:765-774. [PMC free article] [PubMed]
14. Diana, M. A., C. Levenes, K. Mackie, and A. Marty. 2002. Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J. Neurosci. 22:200-208. [PubMed]
15. Di Marzo, V., A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J. C. Schwartz, and D. Piomelli. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691. [PubMed]
16. Di Marzo, V., D. Melck, T. Bisogno, and L. De Petrocellis. 1998. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21:521-528. [PubMed]
17. Dolphin, A. C. 2003. G protein modulation of voltage-gated calcium channels. Pharmacol. Rev. 55:607-627. [PubMed]
18. Exton, J. H. 1996. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu. Rev. Pharmacol. Toxicol. 36:481-509. [PubMed]
19. Freund, T. F., I. Katona, and D. Piomelli. 2003. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83:1017-1066. [PubMed]
20. Fukudome, Y., T. Ohno-Shosaku, M. Matsui, Y. Omori, M. Fukaya, H. Tsubokawa, M. M. Taketo, M. Watanabe, T. Manabe, and M. Kano. 2004. Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Eur. J. Neurosci. 19:2682-2692. [PubMed]
21. Galante, M., and M. A. Diana. 2004. Group I metabotropic glutamate receptors inhibit GABA release at interneuron-Purkinje cell synapses through endocannabinoid production. J. Neurosci. 24:4865-4874. [PubMed]
22. Gamper, N., V. Reznikov, Y. Yamada, J. Yang, and M. S. Shapiro. 2004. Phosphatidylinositol 4,5-bisphosphate signals underlie receptor-specific Gq/11-mediated modulation of N-type Ca2+ channels. J. Neurosci. 24:10980-10992. (Erratum, vol. 25, 2005.) [PubMed]
23. Gingrich, M. B., C. E. Junge, P. Lyuboslavsky, and S. F. Traynelis. 2000. Potentiation of NMDA receptor function by the serine protease thrombin. J. Neurosci. 20:4582-4595. [PubMed]
24. Hamilton, S. E., M. D. Loose, M. Qi, A. I. Levey, B. Hille, G. S. McKnight, R. L. Idzerda, and N. M. Nathanson. 1997. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc. Natl. Acad. Sci. USA 94:13311-13316. [PMC free article] [PubMed]
25. Hartmann, J., R. Blum, Y. Kovalchuk, H. Adelsberger, R. Kuner, G. M. Durand, M. Miyata, M. Kano, S. Offermanns, and A. Konnerth. 2004. Distinct roles of Galpha (q) and Galpha11 for Purkinje cell signaling and motor behavior. J. Neurosci. 24:5119-5130. [PubMed]
26. Hillman, K. L., C. A. Knudson, P. A. Carr, V. A. Doze, and J. E. Porter. 2005. Adrenergic receptor characterization of CA1 hippocampal neurons using real time single cell RT-PCR. Brain Res. Mol. Brain Res. 139:267-276. [PubMed]
27. Howlett, A. C. 2002. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68-69:619-631. [PubMed]
28. Howlett, A. C. 2004. Efficacy in CB1 receptor-mediated signal transduction. Br. J. Pharmacol. 142:1209-1218. [PMC free article] [PubMed]
29. Kammermeier, P. J., V. Ruiz-Velasco, and S. R. Ikeda. 2000. A voltage-independent calcium current inhibitory pathway activated by muscarinic agonists in rat sympathetic neurons requires both Galpha q/11 and Gbeta gamma. J. Neurosci. 20:5623-5629. [PubMed]
30. Kiessling, M., and P. Gass. 1993. Immediate early gene expression in experimental epilepsy. Brain Pathol. 3:381-393. [PubMed]
31. Kim, D., K. S. Jun, S. B. Lee, N. G. Kang, D. S. Min, Y. H. Kim, S. H. Ryu, P. G. Suh, and H. S. Shin. 1997. Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature 389:290-293. [PubMed]
32. Kim, J., M. Isokawa, C. Ledent, and B. E. Alger. 2002. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22:10182-10191. [PubMed]
33. Kleppisch, T., V. Voigt, R. Allmann, and S. Offermanns. 2001. G(alpha)q-deficient mice lack metabotropic glutamate receptor-dependent long-term depression but show normal long-term potentiation in the hippocampal CA1 region. J. Neurosci. 21:4943-4948. [PubMed]
34. Kreitzer, A. C., and W. G. Regehr. 2001. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727. [PubMed]
35. Krestel, H. E., D. R. Shimshek, V. Jensen, T. Nevian, J. Kim, Y. Geng, T. Bast, A. Depaulis, K. Schonig, F. Schwenk, H. Bujard, O. Hvalby, R. Sprengel, and P. H. Seeburg. 2004. A genetic switch for epilepsy in adult mice. J. Neurosci. 24:10568-10578. [PubMed]
36. Lauckner, J. E., B. Hille, and K. Mackie. 2005. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. USA 102:19144-191449. [PMC free article] [PubMed]
37. Lu, Y. M., Z. Jia, C. Janus, J. T. Henderson, R. Gerlai, J. M. Wojtowicz, and J. C. Roder. 1997. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17:5196-5205. [PubMed]
38. Maejima, T., K. Hashimoto, T. Yoshida, A. Aiba, and M. Kano. 2001. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31:463-475. [PubMed]
39. Mantamadiotis, T., T. Lemberger, S. C. Bleckmann, H. Kern, O. Kretz, A. Martin Villalba, F. Tronche, C. Kellendonk, D. Gau, J. Kapfhammer, C. Otto, W. Schmid, and G. Schutz. 2002. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31:47-54. [PubMed]
40. Marsicano, G., S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S. C. Azad, M. G. Cascio, S. O. Gutierrez, M. van der Stelt, M. L. Lopez-Rodriguez, E. Casanova, G. Schutz, W. Zieglgansberger, V. Di Marzo, C. Behl, and B. Lutz. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88. [PubMed]
41. Martin, L. A., and B. E. Alger. 1999. Muscarinic facilitation of the occurrence of depolarization-induced suppression of inhibition in rat hippocampus. Neuroscience 92:61-71. [PubMed]
42. Matsumoto, M., T. Nakagawa, T. Inoue, E. Nagata, K. Tanaka, H. Takano, O. Minowa, J. Kuno, S. Sakakibara, M. Yamada, H. Yoneshima, A. Miyawaki, Y. Fukuuchi, T. Furuichi, H. Okano, K. Mikoshiba, and T. Noda. 1996. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. Nature 379:168-171. [PubMed]
43. Mechoulam, R., M. Spatz, and E. Shohami. 2002. Endocannabinoids and neuroprotection. Sci. STKE 2002:RE5. [Online.] [PubMed]
44. Melis, M., M. Pistis, S. Perra, A. L. Muntoni, G. Pillolla, and G. L. Gessa. 2004. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 24:53-62. [PubMed]
45. Mirotznik, R. R., X. Zheng, and E. F. Stanley. 2000. G-protein types involved in calcium channel inhibition at a presynaptic nerve terminal. J. Neurosci. 20:7614-7621. [PubMed]
46. Miura, M., M. Watanabe, S. Offermanns, M. I. Simon, and M. Kano. 2002. Group I metabotropic glutamate receptor signaling via Galpha q/Galpha 11 secures the induction of long-term potentiation in the hippocampal area CA1. J. Neurosci. 22:8379-8390. [PubMed]
47. Mukhopadhyay, S., J. Y. Shim, A. A. Assi, D. Norford, and A. C. Howlett. 2002. CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling. Chem. Phys. Lipids 121:91-109. [PubMed]
48. Offermanns, S., K. Hashimoto, M. Watanabe, W. Sun, H. Kurihara, R. F. Thompson, Y. Inoue, M. Kano, and M. I. Simon. 1997. Impaired motor coordination and persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking Galphaq. Proc. Natl. Acad. Sci. USA 94:14089-14094. [PMC free article] [PubMed]
49. Offermanns, S., L. P. Zhao, A. Gohla, I. Sarosi, M. I. Simon, and T. M. Wilkie. 1998. Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha q/G alpha 11-mutant mice. EMBO J. 17:4304-4312. [PMC free article] [PubMed]
50. Ohno-Shosaku, T., T. Maejima, and M. Kano. 2001. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729-738. [PubMed]
51. Ohno-Shosaku, T., M. Matsui, Y. Fukudome, J. Shosaku, H. Tsubokawa, M. M. Taketo, T. Manabe, and M. Kano. 2003. Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. Eur. J. Neurosci. 18:109-116. [PubMed]
52. Ohno-Shosaku, T., J. Shosaku, H. Tsubokawa, and M. Kano. 2002. Cooperative endocannabinoid production by neuronal depolarization and group I metabotropic glutamate receptor activation. Eur. J. Neurosci. 15:953-961. [PubMed]
53. Ohno-Shosaku, T., H. Tsubokawa, I. Mizushima, N. Yoneda, A. Zimmer, and M. Kano. 2002. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 22:3864-3872. [PubMed]
54. Ortar, G., A. Ligresti, L. De Petrocellis, E. Morera, and V. Di Marzo. 2003. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65:1473-1481. [PubMed]
55. Pertwee, R. G. 1999. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:635-664. [PubMed]
56. Piomelli, D. 2003. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4:873-884. [PubMed]
57. Savolainen, K. M., and M. R. Hirvonen. 1992. Second messengers in cholinergic-induced convulsions and neuronal injury. Toxicol. Lett. 64-65(Spec. No.):437-445. [PubMed]
58. Stella, N., P. Schweitzer, and D. Piomelli. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778. [PubMed]
59. Sugiura, T., Y. Kobayashi, S. Oka, and K. Waku. 2002. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 66:173-192. [PubMed]
60. Tecott, L. H., L. M. Sun, S. F. Akana, A. M. Strack, D. H. Lowenstein, M. F. Dallman, and D. Julius. 1995. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542-546. [PubMed]
61. van der Stelt, M., M. Trevisani, V. Vellani, L. De Petrocellis, A. Schiano Moriello, B. Campi, P. McNaughton, P. Geppetti, and V. Di Marzo. 2005. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J. 24:3026-3037. [PMC free article] [PubMed]
62. van der Stelt, M., W. B. Veldhuis, M. Maccarrone, P. R. Bar, K. Nicolay, G. A. Veldink, V. Di Marzo, and J. F. Vliegenthart. 2002. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol. Neurobiol. 26:317-346. [PubMed]
63. van der Stelt, M., W. B. Veldhuis, G. W. van Haaften, F. Fezza, T. Bisogno, P. R. Bar, G. A. Veldink, J. F. Vliegenthart, V. Di Marzo, and K. Nicolay. 2001. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21:8765-8771. [PubMed]
64. van Hooft, J. A., R. Giuffrida, M. Blatow, and H. Monyer. 2000. Differential expression of group I metabotropic glutamate receptors in functionally distinct hippocampal interneurons. J. Neurosci. 20:3544-3551. [PubMed]
65. Varma, N., G. C. Carlson, C. Ledent, and B. E. Alger. 2001. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21:RC188. [Online.] [PubMed]
66. Wettschureck, N., A. Moers, T. Hamalainen, T. Lemberger, G. Schütz, and S. Offermanns. 2004. Heterotrimeric G proteins of the Gq/11 family are crucial for the induction of maternal behavior in mice. Mol. Cell. Biol. 24:8048-8054. [PMC free article] [PubMed]
67. Wettschureck, N., H. Rutten, A. Zywietz, D. Gehring, T. M. Wilkie, J. Chen, K. R. Chien, and S. Offermanns. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat. Med. 7:1236-1240. [PubMed]
68. Wilson, R. I., and R. A. Nicoll. 2002. Endocannabinoid signaling in the brain. Science 296:678-682. [PubMed]
69. Wilson, R. I., and R. A. Nicoll. 2001. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592. [PubMed]
70. Zhang, J., D. Zhang, J. S. McQuade, M. Behbehani, J. Z. Tsien, and M. Xu. 2002. c-fos regulates neuronal excitability and survival. Nat. Genet. 30:416-420. [PubMed]

Articles from Molecular and Cellular Biology are provided here courtesy of American Society for Microbiology (ASM)
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...